
CHCC 2026 is a flagship industry platform for hospital construction, bringing together solutions across hospital planning, architectural design, MEP systems, interior environment, specialized medical engineering, medical equipment, smart hospital technologies, logistics, operations, and medical robotics.
Taking place from May 23 to 25, 2026 at the National Convention & Exhibition Center (Tianjin), the event is positioned as a 100,000 sqm platform with 8 themed pavilions, 40 zones, and more than 100 conference sessions and brand activities, creating a one-stop destination for learning, networking, sourcing, and project collaboration across the healthcare infrastructure ecosystem.




Reed Sinopharm Exhibitions is the exhibition and conference organizer in China's healthcare sector, established as a joint venture between Sinopharm (China's leading state-owned healthcare enterprise) and RX (a globally leading exhibition organizer). This strategic alliance combines deep industry insight with a global perspective.
With over 40 years of rooting in the Chinese pharmaceutical market, its flagship event API China serves as a vital gateway for global pharma companies to access China. Reed Sinopharm organizes dozens of professional exhibitions and conferences annually, covering the entire pharmaceutical value chain from R&D and manufacturing to distribution, and is widely recognized as the "barometer" of China's pharmaceutical industry.





Reed Sinopharm Exhibitions is the exhibition and conference organizer in China's healthcare sector, established as a joint venture between Sinopharm (China's leading state-owned healthcare enterprise) and RX (a globally leading exhibition organizer). This strategic alliance combines deep industry insight with a global perspective.
With over 40 years of rooting in the Chinese pharmaceutical market, its flagship event API China serves as a vital gateway for global pharma companies to access China. Reed Sinopharm organizes dozens of professional exhibitions and conferences annually, covering the entire pharmaceutical value chain from R&D and manufacturing to distribution, and is widely recognized as the "barometer" of China's pharmaceutical industry.